AstraZeneca, the pharmaceutical company behind the Oxford COVID-19 vaccine, has selected six Israeli healthtech startups for its annual innovation scale-up program.
During the nine-month program it will share insights, expertise, resources, connections, and guidance to accelerate their international growth.
The startups all work in the areas of oncology, cardiovascular, renal and metabolic diseases, vaccines and infections, and respiratory and immunology. Every participating company receives support tailored to its unique needs.
The companies are:
Curesponse, a cancer diagnostics company developing a three-dimensional tissue culture system for modeling cancer growth and drug response;
Lynx.MD, a secure platform for sharing medical data to accelerate research and medical developments;
Pangea Biomed, whose platform uses AI to analyze cancerous tumors and match patients with the most effective treatment;
QuantHealth, which enables pharma and biotech companies to conduct thousands of clinical trials within minutes to accelerate drug development;
Quris.ai, an AI prediction platform that tests drug safety and is designed to accurately predict which drug candidates will work safely in humans, and;
Rhino Health, which connects data across hospital systems to enable AI development, validation, monitoring and product maintenance.
This is the third cohort of the program since AstraZeneca launched the BeyondBio Scale program in 2019.